Trial Profile
A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety of RVL-1201 in the Treatment of Acquired Blepharoptosis (Study RVL-1201-203)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Oxymetazoline (Primary)
- Indications Blepharoptosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Osmotica Pharmaceutical; RevitaLid; RVL; RVL Pharmaceuticals
- 03 Apr 2023 According to a RVL Pharmaceuticals media release, company announced today that its prescription eye drop Upneeq, 0.1% has been selected winner in the professional treatment category as 'Best Eye Drop for Drooping Lids' in the NewBeauty 13th Annual Beauty Awards, which hits newsstand on 4 Apr, 2023. Also, previously,Upneeq was awarded the 'Best Innovation' in 2022 by this definitive authority in beauty.
- 09 Jul 2020 According to an Osmotica Pharmaceutical media release, the company will host a Investor Call to discuss approval, key elements of the clinical data and commercial plans.
- 09 Jul 2020 According to an Osmotica Pharmaceutical media release, the U.S. Food and Drug Administration (FDA) has approved Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1% for the treatment for acquired blepharoptosis in adults.